Intec Pharma to Participate in the Ladenburg Thalmann 2017 Healthcare Conference

JERUSALEM, September 20, 2017 /PRNewswire/ --

Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced that management will participate in the Ladenburg Thalmann 2017 Healthcare Conference to be held September 26, 2017 at the Sofitel Hotel in New York City.

Date and Time of Presentation: Tuesday, September 26, 2017 at 3:00 p.m. Eastern time

Venue: Sofitel New York Hotel

Format: Company presentation

Presenter: Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma

Mr. Meckler's presentation will be webcast live and can be accessed on the Events section of the Company's website at http://www.intecpharma.com.  

About Intec Pharma Ltd. 

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

        

        Contacts: 
        Jeffrey A. Meckler 
        Chief Executive Officer 
        Intec Pharma Ltd. 
        +1-646-374-8050 
        jeffrey@intecpharma.com   

        Anne Marie Fields 
        Senior Vice President 
        LHA Investor Relations 
        +1-212-838-3777 
        afields@lhai.com 

SOURCE Intec Pharma Ltd.